Clare C. Bailey

Lower Maudlin Street
Bristol, ENG, United Kingdom

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 89 publications

Enhanced Macular Imaging Referral Pathway: Bridging Community Optometrists and Hospital Specialists for Smarter Eye Care.

Enhanced Macular Imaging Referral Pathway: Bridging Community Optometrists and Hospital Specialists for Smarter Eye Care.

Journal: Ophthalmology and therapy

Published: May 14, 2026

SPECTRUM: Early clinical experience from the first global real-world study of aflibercept 8 mg in patients with diabetic macular oedema.

SPECTRUM: Early clinical experience from the first global real-world study of aflibercept 8 mg in patients with diabetic macular oedema.

Journal: Eye (London, England)

Published: April 24, 2026

Modified Delphi expert consensus on the optimal intravitreal treatment pathway for centre involving diabetic macular oedema patients within the National Health Service.

Modified Delphi expert consensus on the optimal intravitreal treatment pathway for centre involving diabetic macular oedema patients within the National Health Service.

Journal: BMJ open ophthalmology

Published: February 08, 2026

SPECTRUM: early clinical experience from the first global real-world study of aflibercept 8 mg in patients with neovascular age-related macular degeneration.

SPECTRUM: early clinical experience from the first global real-world study of aflibercept 8 mg in patients with neovascular age-related macular degeneration.

Journal: Eye (London, England)

Published: November 27, 2025

Infographic: SPECTRUM: study design of the global real-world study of aflibercept 8 mg in the treatment of neovascular age-related macular degeneration and diabetic macular edema.

Infographic: SPECTRUM: study design of the global real-world study of aflibercept 8 mg in the treatment of neovascular age-related macular degeneration and diabetic macular edema.

Journal: Eye (London, England)

Published: September 15, 2025

Pharmacological principles of intravitreal drug therapy and their implications for clinical practice: a primer for the ophthalmologist.

Pharmacological principles of intravitreal drug therapy and their implications for clinical practice: a primer for the ophthalmologist.

Journal: Eye (London, England)

Published: September 09, 2025

Automated data collection from an electronic medical record for a prospective real-world study in patients with retinal disease (VOYAGER).

Automated data collection from an electronic medical record for a prospective real-world study in patients with retinal disease (VOYAGER).

Journal: Clinical trials (London, England)

Published: August 31, 2025

Aflibercept 8 mg treat-and-extend pathway for the treatment of neovascular age-related macular degeneration: guidance from a UK expert panel.

Aflibercept 8 mg treat-and-extend pathway for the treatment of neovascular age-related macular degeneration: guidance from a UK expert panel.

Journal: Eye (London, England)

Published: May 15, 2025

Real-world treatment patterns and visual outcomes of faricimab in patients with diabetic macular oedema in the UK at 12 months: the FARWIDE-DMO study.

Real-world treatment patterns and visual outcomes of faricimab in patients with diabetic macular oedema in the UK at 12 months: the FARWIDE-DMO study.

Journal: Eye (London, England)

Published: May 13, 2025

Real-world treatment patterns and visual outcomes of faricimab in patients with neovascular age-related macular degeneration in the UK at 12 months: the FARWIDE-nAMD study.

Real-world treatment patterns and visual outcomes of faricimab in patients with neovascular age-related macular degeneration in the UK at 12 months: the FARWIDE-nAMD study.

Journal: Eye (London, England)

Published: April 07, 2025

Aflibercept 2 mg for Neovascular Age-Related Macular Degeneration: XTEND at 3 Years.

Aflibercept 2 mg for Neovascular Age-Related Macular Degeneration: XTEND at 3 Years.

Journal: Ophthalmologica. Journal international d'ophtalmologie. International journal of ophthalmology. Zeitschrift fur Augenheilkunde

Published: March 17, 2025

Tropomyosin-Related Kinase Receptor Type B Agonism in Geographic Atrophy-The Translational Challenges from Preclinical Data to a First-in-Human Trial.

Tropomyosin-Related Kinase Receptor Type B Agonism in Geographic Atrophy-The Translational Challenges from Preclinical Data to a First-in-Human Trial.

Journal: Ophthalmology science

Published: March 13, 2025

Showing 1-12 of 89

Last Updated: 09/26/2026